RecallRadar

FDA Drug recall D-0539-2025

EVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 9…

On 2025-07-30 the FDA classified a Class II recall of EVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 9… by Mckesson Medical Surgical Corporate Office, citing CGMP Deviations; potential temperature excursions due to transit delays.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0539-2025
ClassificationClass II
Statusongoing
Initiated2025-04-21
Published2025-07-30
Last updated2026-09-13 11:52 UTC
CompanyMckesson Medical Surgical Corporate Office
DistributionFL, OH, VA

Product

EVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-880-02.

Reason

CGMP Deviations; potential temperature excursions due to transit delays

Identifiers

ndc55513-880-01
ndc55513-880-02
ndc55513-998-01
ndc55513-998-02
ndc55513-509-01
ndc55513-509-02
code_infoLot: 1178382, Expiration date: 3/31/2027

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0539-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.